| Greil, Richard |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
DIsCOvER, NCT03984214: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 3 | 109 | Europe | Dronabinol in Oral Dosage Form, BX-1, Placebo in Oral Dosage Form | Arbeitsgemeinschaft medikamentoese Tumortherapie, Medical University of Graz, Unidata Geodesign, Bionorica SE | Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic | 09/24 | 09/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
| Recruiting | 3 | 734 | Europe, Japan, US, RoW | NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy | NovoCure GmbH | Metastatic Non-small Cell Lung Cancer | 10/28 | 10/28 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
|
|
| Active, not recruiting | 2 | 63 | Europe | Patritumab deruxtecan, HER3-DXd | MedSIR, Daiichi Sankyo | Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | 12/25 | 10/26 | | |
LUNAR-4, NCT06558799: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 69 | Europe | NovoTTF-200T, Pembrolizumab | NovoCure GmbH | Non-Small Cell Lung Cancer (NSCLC) | 06/26 | 10/26 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
EXPAND, NCT05714345: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy |
|
|
| Active, not recruiting | 2 | 70 | Europe, US | ALLO-647, Fludarabine, Cyclophosphamide, ALLO-501A | Allogene Therapeutics | Relapsed/Refractory Large B Cell Lymphoma | 02/24 | 10/29 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
NCT04891809: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM |
|
|
| Recruiting | 2 | 198 | Europe, RoW | Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral | Arbeitsgemeinschaft medikamentoese Tumortherapie, University of Navarra, Medical University of Vienna, Assign Data Management and Biostatistics GmbH, WiSP GmbH, Sanofi | Newly Diagnosed Multiple Myeloma | 12/27 | 12/28 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
| Recruiting | 1 | 12 | Europe | APN401 | invIOs GmbH | Advanced Solid Tumor | 03/24 | 03/24 | | |
| Completed | 1 | 15 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT01595295: Registry on Hypomethylating Agents in Myeloid Neoplasms |
|
|
| Completed | N/A | 1500 | Europe, RoW | non interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia | 12/21 | 12/21 | | |
| Recruiting | N/A | 1000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Infectious Disease, COVID-19 | 12/21 | 12/21 | | |
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry |
|
|
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Lymphocytic Leukemia | 12/27 | 12/27 | | |
NCT03301493: Genomic Testing and Resulting Medical Decisions |
|
|
| Recruiting | N/A | 1000 | Europe | Genomic testing | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca | Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms | 12/24 | 12/24 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Recruiting | N/A | 4000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | 12/33 | 12/33 | | |
SOUND, NCT05032092: Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer |
|
|
| Recruiting | N/A | 235 | Europe | Next Generation Sequencing, FoundationOne®Liquid CDx, FoundationOne® CDx, Biomarker Monitoring, AVENIO ctDNA Expanded Kit | Medical University of Graz | Locally Advanced Carcinoma, Metastatic Cancer | 07/25 | 06/26 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
ABCSG C08, NCT03822572: -Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer |
|
|
| Recruiting | N/A | 788 | Europe | endurance exercise, control | Austrian Breast & Colorectal Cancer Study Group, Oberösterreichische Krebshilfe | Colorectal Carcinoma | 12/26 | 12/26 | | |
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | N/A | 605 | Europe | Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro® | iOMEDICO AG, BeiGene Switzerland GmbH | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma | 08/28 | 08/28 | | |
| Recruiting | N/A | 3000 | Europe | Non-interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Myeloid Diseases | 04/29 | 04/30 | | |
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lung Cancer, NSCLC Stage IV, NSCLC, Stage III, SCLC, Extensive Stage, SCLC, Limited Stage | 08/30 | 08/30 | | |
| Li, Ping |
NCT06381323: The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism |
|
|
| Recruiting | 4 | 55 | RoW | Finerenone, Nifedipine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist | 03/27 | 04/27 | | |
NCT06256289: Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome |
|
|
| Not yet recruiting | 4 | 50 | NA | Canagliflozin 100mg Tab, Invokana, Metformin Hydrochloride, Glucophage | Ping Li,MD | Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease | 04/25 | 04/25 | | |
NCT04939441: Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) |
|
|
| Active, not recruiting | 4 | 100 | RoW | Tenofovir alafenamide, Vemlidy® | Jidong Jia, Beijing Ditan Hospital, ShuGuang Hospital, Tianjin Third Central Hospital, Huashan Hospital, The Sixth Peoples Hospital of Zhengzhou, Tianjin Second People's Hospital, Ruijin Hospital, Shanghai East Hospital | Chronic Hepatitis B | 05/24 | 05/25 | | |
NCT05814770: Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism |
|
|
| Not yet recruiting | 4 | 96 | NA | Finerenone, Kerendia, Spironolactone | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, National Key Research and Development Program of China, National Natural Science Foundation of China | Primary Aldosteronism, Hypertension | 03/25 | 03/26 | | |
NDKD, NCT06110130: Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With |
|
|
| Recruiting | 4 | 60 | US | Empagliflozin 10 MG, Placebo | Washington D.C. Veterans Affairs Medical Center, Boehringer Ingelheim | Chronic Kidney Diseases | 12/25 | 12/26 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
NCT06677879: A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. |
|
|
| Recruiting | 2 | 780 | RoW | Proton radiotherapy, Photon radiotherapy | Shanghai Proton and Heavy Ion Center | Breast Cancer | 07/26 | 07/28 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
| Recruiting | 2 | 54 | RoW | proton plus carbon ion radiation | Shanghai Proton and Heavy Ion Center | Prostate Cancer | 05/25 | 05/26 | | |
| Recruiting | 2 | 140 | RoW | carbon ion irradation, Carbon Ion Irradiation With SIB | Shanghai Proton and Heavy Ion Center | Localized Prostate Cancer | 07/25 | 07/28 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
SPHIC-TR-BCa2022-02, NCT05692674: A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction |
|
|
| Recruiting | 2 | 67 | RoW | adjuvant hypofractionated intensity-modulated proton radiotherapy | Shanghai Proton and Heavy Ion Center | Breast Cancer | 09/28 | 09/28 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
| Recruiting | 1 | 30 | RoW | carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Radiotherapy, Prostate Cancer | 12/22 | 06/23 | | |
NCT06375161: Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. |
|
|
| Recruiting | 1 | 12 | RoW | anti-CD19-CAR-T cells | Shanghai Tongji Hospital, Tongji University School of Medicine | B Cell Malignancies | 12/25 | 12/39 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
| Recruiting | 1 | 24 | RoW | proton plus carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Triple Negative Breast Cancer, HER2-positive Breast Cancer | 10/25 | 01/26 | | |
CHESS1901, NCT03990753: Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (/APPHA1901) |
|
|
| Recruiting | N/A | 1000 | RoW | esophagogastroduodenoscopy | Nanfang Hospital of Southern Medical University, Southern Medical University, China, LanZhou University, Zhongda Hospital, Medical School, Southeast University, Guangdong Second Provincial General Hospital, Xingtai People's Hospital, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Tianjin Second People's Hospital, Zhejiang University Lishui Hospital, The Second Hospital of Anhui Medical University, The Sixth People's Hospital of Shenyang, Xi'an Gaoxin Hospital, King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn University, Ankara University | Compensated Cirrhosis | 06/21 | 06/22 | | |
| Not yet recruiting | N/A | 5000 | RoW | Endovascular Therapy | Chinese Academy of Medical Sciences, Fuwai Hospital | Renal Artery Obstruction, Hypertension, Renovascular | 04/22 | 04/24 | | |
NCT04108169: Association Between S-LAAO and Adverse Cardiovascular Events Among Patients Undergoing Coronary Artery Bypass Grafting. |
|
|
| Recruiting | N/A | 240 | RoW | Left atrial appendage occlusion surgery | Beijing Institute of Heart, Lung and Blood Vessel Diseases | Heart Surgery | 10/22 | 01/23 | | |
NCT02739659: Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer |
|
|
| Recruiting | N/A | 73 | RoW | carbon-ion radiotherapy | Shanghai Proton and Heavy Ion Center | Prostate Carcinoma | 12/22 | 12/24 | | |
NCT05392712: Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis |
|
|
| Recruiting | N/A | 430 | RoW | Magnetometer | Qilu Hospital of Shandong University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Weifang People's Hospital, Linyi People's Hospital, Jining First People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing Emergency Medical Center, Guangdong Provincial Hospital of Traditional Chinese Medicine, First People's Hospital of Hangzhou, Central hospital Affiliated to Shandong First Medical University, Weihai Central Hospital, Heze Municipal Hospital | Chest Pain, Acute Coronary Syndrome, Myocardial Infarction | 08/24 | 12/24 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
NCT04833192: Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism |
|
|
| Recruiting | N/A | 202 | RoW | experimental group | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Adrenal Incidentaloma, Subclinical Hypercortisolism | 04/23 | 12/23 | | |
NCT05826080: Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism |
|
|
| Recruiting | N/A | 59 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Aldosterone-Producing Adenoma, Idiopathic Hyperaldosteronism | 10/23 | 09/24 | | |
NCT05896826: Magnetocardiography in the Accurate Identification of Myocardial Infarction |
|
|
| Recruiting | N/A | 500 | RoW | Magnetometer | Qilu Hospital of Shandong University, Chongqing Emergency Medical Center, Weifang People's Hospital, Linyi People's Hospital, Weihai Central Hospital, Jining First People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital Xi'an Jiaotong University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Central hospital Affiliated to Shandong First Medical University, Heze Municipal Hospital, First People's Hospital of Hangzhou | Chest Pain, Acute Coronary Syndrome, Myocardial Infarction | 10/24 | 12/24 | | |
| Recruiting | N/A | 240 | RoW | Carvedilol 12.5 MG, Nucleos(t)ide Analogues | Beijing Friendship Hospital | Liver Cirrhosis, Portal Hypertension | 10/24 | 10/24 | | |
TAILOR-TAVR, NCT05511792: Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0) |
|
|
| Recruiting | N/A | 206 | RoW | TAVR for BAV Using Down Sizing with the Evolut Pro platform, Down Sizing Strategy, TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform, Standard Sizing Strategy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aortic Stenosis With Bicuspid Valve | 06/25 | 06/29 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT03261934: Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation |
|
|
| Recruiting | N/A | 2000 | RoW | No intervention | Beijing University of Chinese Medicine, The University of Science and Technology of China, China Academy of Chinese Medical Sciences, Harvard Medical School (HMS and HSDM) | Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation | 12/30 | 12/30 | | |
ACTRN12622000019707: Effects of recorded maternal voice on heart rate and anthropometric parameters in premature infants: A randomized controlled trial |
|
|
| Completed | N/A | 108 | | | Ping Li, Ping Li | heart rate, anthropometric parameters | | | | |
NCT04289701: Hypertension Registry of "Hypertension Prevention and Control Initiative in China" |
|
|
| Recruiting | N/A | 200000 | RoW | Health Services for Systematic Hypertension Management | Chinese Academy of Medical Sciences, Fuwai Hospital | Hypertension | 12/22 | 12/24 | | |
NCT05357456: Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study |
|
|
| Recruiting | N/A | 62 | RoW | Cognitive function assessment; functional magnetic resonance imaging, fMRI, laparoscopic adrenal surgery | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Autonomous Cortisol Secretion, Adrenal Incidentaloma, Non-functioning Adrenal Adenomas | 10/24 | 10/26 | | |
| Aftimos, Philippe |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT03810872: An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation |
|
|
| Recruiting | 2 | 87 | Europe | Afatinib, Paclitaxel | AZ-VUB | Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation | 12/20 | 12/22 | | |
| Active, not recruiting | 2 | 65 | Europe | Entrectinib, Letrozole, Goserelin | Jules Bordet Institute, Hoffmann-La Roche | Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer | 01/25 | 01/25 | | |
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 400 | Europe, US, RoW | Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Cancer, Metastatic Breast Cancer | 12/24 | 08/26 | | |
| Active, not recruiting | 1 | 500 | Europe, Japan, US, RoW | LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab | Eli Lilly and Company | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer | 06/20 | 12/27 | | |
| Recruiting | N/A | 1000 | Europe, RoW | metastatic lesion biopsy | Breast International Group, Jules Bordet Institute, Frontier Science & Technology Research Foundation, Inc. | Metastatic Breast Cancer | 12/27 | 03/31 | | |
NCT04641676: A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center |
|
|
| Recruiting | N/A | 1000 | Europe | NGS testing | The Belgian Society of Medical Oncology, Foundation Medicine, Sciensano, Roche Pharma AG | Metastatic Cancer, Local Tumor Invasion | 09/22 | 12/22 | | |
NCT03873103: The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment |
|
|
| Recruiting | N/A | 1000 | Europe | | The Belgian Society of Medical Oncology | Metastatic Cancer | 12/23 | 12/23 | | |
| Bartsch, Rupert |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Completed | 2 | 15 | Europe | Trastuzumab deruxtecan, Ds8201a, Enhertu | Medical University of Vienna, Daiichi Sankyo, Inc. | Breast Cancer Stage IV | 05/23 | 05/23 | | |
|
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
|
|
| Active, not recruiting | 2 | 63 | Europe | Patritumab deruxtecan, HER3-DXd | MedSIR, Daiichi Sankyo | Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | 12/25 | 10/26 | | |
TUXEDO-2, NCT05866432: Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases |
|
|
| Recruiting | 2 | 20 | Europe | Datopotamab deruxtecan, S-1062a | Medical University of Vienna, Daiichi Sankyo, Inc. | Breast Cancer Stage IV | 05/26 | 05/26 | | |
TRACE, NCT05253911: Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. |
|
|
| Recruiting | N/A | 300 | Europe | TUKYSA® | iOMEDICO AG, Seagen Inc. | HER2-positive Breast Cancer | 05/27 | 05/27 | | |
| Petru, Edgar |
| Active, not recruiting | 3 | 502 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
